Literature DB >> 32543918

Exhausted and outnumbered: CD4+ T cells in the myeloma battlefield.

Elisabet E Manasanch1, Morie A Gertz2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32543918      PMCID: PMC7665850          DOI: 10.1080/10428194.2020.1779261

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


× No keyword cloud information.
  18 in total

1.  Low absolute CD4+ T cell counts in peripheral blood predict poor prognosis in patients with newly diagnosed multiple myeloma.

Authors:  Yan Gu; Yuanyuan Jin; Jie Ding; Wu Yujie; Qinglin Shi; Xiaoyan Qu; Sishu Zhao; Jianyong Li; Chen Lijuan
Journal:  Leuk Lymphoma       Date:  2020-04-23

2.  Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.

Authors:  Peter M Voorhees; Jonathan L Kaufman; Jacob Laubach; Douglas W Sborov; Brandi Reeves; Cesar Rodriguez; Ajai Chari; Rebecca Silbermann; Luciano J Costa; Larry D Anderson; Nitya Nathwani; Nina Shah; Yvonne A Efebera; Sarah A Holstein; Caitlin Costello; Andrzej Jakubowiak; Tanya M Wildes; Robert Z Orlowski; Kenneth H Shain; Andrew J Cowan; Sean Murphy; Yana Lutska; Huiling Pei; Jon Ukropec; Jessica Vermeulen; Carla de Boer; Daniela Hoehn; Thomas S Lin; Paul G Richardson
Journal:  Blood       Date:  2020-08-20       Impact factor: 22.113

Review 3.  High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications.

Authors:  Chutima Kunacheewa; Elisabet E Manasanch
Journal:  Best Pract Res Clin Haematol       Date:  2020-01-25       Impact factor: 3.020

4.  The Frequency and clinical Implications of Lymphocyte Subsets and Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma Patients.

Authors:  Asmaa M Zahran; Mona M Sayed; Engy A Shafik; Salah M Khallaf; Wael M Mohamed; Helal F Hetta
Journal:  Egypt J Immunol       Date:  2019-07

5.  Lymphoid subsets and prognostic factors in multiple myeloma. Cooperative Group for the Study of Monoclonal Gammopathies.

Authors:  J F San Miguel; M González; A Gascón; M J Moro; J M Hernández; F Ortega; R Jiménez; L Guerras; M Romero; F Casanova
Journal:  Br J Haematol       Date:  1992-03       Impact factor: 6.998

6.  Baseline immune dysregulation in autologous stem cell transplant recipients is associated with a 'graft versus host'-like syndrome and poor outcomes.

Authors:  Theodora Anagnostou; Reona Sakemura; Cynthia L Forsman; Mrinal S Patnaik; Jonas Paludo; Dennis A Gastineau; Francis K Buadi; Luis F Porrata; Shaji K Kumar; Morie A Gertz; Matha Q Lacy; Angela Dispenzieri; Wilson I Gonsalves; Julia S Lehman; William J Hogan; Shahrukh K Hashmi; Hassan Alkhateeb; Mithun V Shah; Mark R Litzow; Saad S Kenderian
Journal:  Bone Marrow Transplant       Date:  2020-03-11       Impact factor: 5.483

7.  Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

Authors:  Sattva S Neelapu; Frederick L Locke; Nancy L Bartlett; Lazaros J Lekakis; David B Miklos; Caron A Jacobson; Ira Braunschweig; Olalekan O Oluwole; Tanya Siddiqi; Yi Lin; John M Timmerman; Patrick J Stiff; Jonathan W Friedberg; Ian W Flinn; Andre Goy; Brian T Hill; Mitchell R Smith; Abhinav Deol; Umar Farooq; Peter McSweeney; Javier Munoz; Irit Avivi; Januario E Castro; Jason R Westin; Julio C Chavez; Armin Ghobadi; Krishna V Komanduri; Ronald Levy; Eric D Jacobsen; Thomas E Witzig; Patrick Reagan; Adrian Bot; John Rossi; Lynn Navale; Yizhou Jiang; Jeff Aycock; Meg Elias; David Chang; Jeff Wiezorek; William Y Go
Journal:  N Engl J Med       Date:  2017-12-10       Impact factor: 91.245

8.  T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma.

Authors:  Alfred L Garfall; Ehren K Dancy; Adam D Cohen; Wei-Ting Hwang; Joseph A Fraietta; Megan M Davis; Bruce L Levine; Don L Siegel; Edward A Stadtmauer; Dan T Vogl; Adam Waxman; Aaron P Rapoport; Michael C Milone; Carl H June; J Joseph Melenhorst
Journal:  Blood Adv       Date:  2019-10-08

9.  A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis.

Authors:  Elisabet E Manasanch; Guangchun Han; Rohit Mathur; Yun Qing; Zheng Zhang; Hans Lee; Donna M Weber; Behrang Amini; Zuzana Berkova; Karina Eterovic; Shaojun Zhang; Jianhua Zhang; Xingzhi Song; Xizeng Mao; Margaret Morgan; Lei Feng; Veera Baladandayuthapani; Andrew Futreal; Linghua Wang; Sattva S Neelapu; Robert Z Orlowski
Journal:  Blood Adv       Date:  2019-08-13

10.  Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.

Authors:  Shannon L Maude; Theodore W Laetsch; Jochen Buechner; Susana Rives; Michael Boyer; Henrique Bittencourt; Peter Bader; Michael R Verneris; Heather E Stefanski; Gary D Myers; Muna Qayed; Barbara De Moerloose; Hidefumi Hiramatsu; Krysta Schlis; Kara L Davis; Paul L Martin; Eneida R Nemecek; Gregory A Yanik; Christina Peters; Andre Baruchel; Nicolas Boissel; Francoise Mechinaud; Adriana Balduzzi; Joerg Krueger; Carl H June; Bruce L Levine; Patricia Wood; Tetiana Taran; Mimi Leung; Karen T Mueller; Yiyun Zhang; Kapildeb Sen; David Lebwohl; Michael A Pulsipher; Stephan A Grupp
Journal:  N Engl J Med       Date:  2018-02-01       Impact factor: 91.245

View more
  1 in total

1.  Reference ranges of T lymphocyte subsets by single-platform among healthy population in southwest China.

Authors:  Bin Wei; Ying Guo; Liangjun Zhang; Huixiu Zhong; Qiang Miao; Lin Yan; Yangjuan Bai; Weihua Feng; Weiping Liu; Qian Niu; Yi Li
Journal:  BMC Immunol       Date:  2021-12-20       Impact factor: 3.615

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.